Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CANbridge
Asia
BeiGene, Astellas, Mundipharma and more—Fierce Pharma Asia
BeiGene doubles sales in the first quarter and snags a conditional nod for a PARP inhibitor. Astellas drops out of a licensing deal with Cytokinetics.
Angus Liu
May 7, 2021 11:01am
CANbridge buys liver-targeted gene therapies from LogicBio
May 4, 2021 7:40am
Biogen-Eisai, Lonsurf and more—FiercePharmaAsia
Oct 26, 2018 10:03am
FiercePharmaAsia—Takeda, GSK, Novartis-Laekna and more
Aug 3, 2018 9:55am
FiercePharmaAsia—Gardasil, Lupin, CANbridge and more
May 26, 2017 9:11am
